Tin tức & Cập nhật

Eosinophil levels do not influence outcomes with triple combo asthma inhaler
Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023

Treatment with fixed-dose asthma inhaler combination of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) helps improve lung function and reduce exacerbations as compared with MF/IND and fluticasone/salmeterol (FLU/SAL), regardless of baseline eosinophil levels, according to a post hoc analysis of the IRIDIUM study.

Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023
Subsequent pregnancies in women with peripartum cardiomyopathy tied to adverse events
Subsequent pregnancies in women with peripartum cardiomyopathy tied to adverse events
07 Jul 2023

Subsequent pregnancies (SSPs) may lead to adverse outcomes in women with peripartum cardiomyopathy (PPCM), reveals a study, noting that the normalization of left ventricular function is not an assurance for a positive outcome in SSPs.

Subsequent pregnancies in women with peripartum cardiomyopathy tied to adverse events
07 Jul 2023
Jaktinib superior to hydroxyurea in myelofibrosis
Jaktinib superior to hydroxyurea in myelofibrosis
07 Jul 2023 bởiStephen Padilla

Jaktinib, a novel JAK and AVCR1 inhibitor, is more effective than hydroxyurea in patients with myelofibrosis, resulting in better spleen response with improved symptom response and less cytopenias, according to the results of a phase III study presented at EHA 2023.

Jaktinib superior to hydroxyurea in myelofibrosis
07 Jul 2023
Objective type 2 MI tied to higher mortality risk
Objective type 2 MI tied to higher mortality risk
07 Jul 2023

Outcomes are significantly worse in patients diagnosed with type 2 myocardial infarction (MI) with objective evidence of myocardial ischaemia compared with those with myocardial injury and subjective type 2 MI, reports a study.

Objective type 2 MI tied to higher mortality risk
07 Jul 2023
Virtual ward feasible home-based care strategy for high-risk COVID-19 patients
Virtual ward feasible home-based care strategy for high-risk COVID-19 patients
07 Jul 2023
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023